Which are High-impact clinical trials that may generate promising results for improving kidney health? Dr Kartikeya Kohli1 Nov 2024 8:00 PM ISTThe results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney...
Finerenone improves long-term survival benefits in patients with worsening heart failure, finds study Jacinthlyn Sylvia18 Oct 2024 8:00 AM ISTA recent study published in the Journal of American Medical Association showed a projection that long-term finerenone medication can increase...
FINEARTS-HF Trial: Finerenone Offers Significant Benefits for HF Patients Following Recent Worsening Events Dr. Prem Aggarwal1 Oct 2024 6:00 AM ISTUSA: The FINEARTS-HF trial revealed that the benefit-risk profile of finerenone (Kerendia) for heart failure with mildly reduced or preserved ejection...
Finerenone may reduce worsening heart failure and cardiovascular death, finds study, ESC 2024 Dr. Kamal Kant Kohli4 Sept 2024 6:00 AM ISTFinerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and...
Medical Bulletin 03/ September /2024 Dr. Garima Soni3 Sept 2024 3:00 PM ISTHere are the top medical news of the day:Does Continuing Beta-Blockers After a Heart Attack Make a Difference? New Study Sheds Lights New research...
Finerenone Reduces Heart Failure Events and Cardiovascular Deaths: FINEARTS-HF trial Dr. Garima Soni3 Sept 2024 9:00 AM ISTRecent research presented at ESC Congress 2024 reveals that finerenone decreased the incidence of heart failure events and cardiovascular deaths in...
FINEARTS-HF Study Shows Finerenone Cuts CV death and Heart Failure Events in HFmrEF/HFpEF Patients Medha Baranwal30 Aug 2024 9:00 AM ISTUSA: Topline results from the FINEARTS-HF trial have revealed that finerenone (Kerendia), a nonsteroidal selective mineralocorticoid receptor...
Medical Bulletin 07/ August/ 2024 Dr. Nandita Mohan7 Aug 2024 3:00 PM ISTHere are the top medical news for the day:New Study Reveals Link Between Obesity and Increased Risk of Heart FailureA recent study led by Johns...
Study shows SGLT2i or Finerenone Added to RAAS Inhibitors Offers Kidney and Heart Protection for Diabetics with CKD Dr. Nandita Mohan7 Aug 2024 8:00 AM ISTType 2 diabetes (T2D) is the leading cause of end-stage kidney disease (ESKD) globally. The presence of both T2D and CKD poses a major public health...
Add on SGLT2i or finerenone to RAAS inhibitor may provide kidney and CV protection in diabetics with CKD: Study Dr. Shravani Dali5 Aug 2024 9:00 AM ISTAdd on SGLT2i or finerenone to RAAS inhibitor may provide kidney and CV protection in diabetics with CKD suggests BMC nephrology.Given the substantial...
Finerenone and dapagliflozin combo significantly reduced albuminuria in non-diabetic CKD patients: Study Aditi20 March 2024 7:30 PM ISTThe effectiveness of dapagliflozin and finerenone in reducing albuminuria and slowing the progression of chronic kidney disease (CKD) has been...
Sun Pharma gets non-exclusive rights to market second brand of Finerenone in India Ruchika Sharma19 Jan 2024 11:17 AM ISTBayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa.
